The early administration of tranexamic acid (TXA) to bleeding trauma patients reduces all-cause mortality without increasing the risk of vascular occlusive events. Indeed, the risk of arterial thrombosis appears to be reduced with TXA. In this commentary we hypothesize that TXA has an antithrombotic effect and explore potential mechanisms. These include inhibition of the inflammatory effects of plasmin, effects on platelets and effects on factors V and VIII. If proven, these antithrombotic effects would have major implications for the systemic use of TXA in surgical patients, where TXA has been clearly shown to reduce bleeding.

Polls results

On a scale of 1 to 10, rate how much this article will change your clinical practice?

NO change
BIG change
100% Article relates to my practice (6/6)
0% Article does not relate to my practice (0/6)
0% Undecided (0/6)

Will this article lead to more cost-effective healthcare?

100% Yes (6/6)
0% No (0/6)
0% Undecided (0/6)

Was this article biased? (commercial or personal)

0% Yes (0/6)
83% No (5/6)
16% Undecided (1/6)

What level of evidence do you think this article is?

0% Level 1 (0/6)
16% Level 2 (1/6)
33% Level 3 (2/6)
16% Level 4 (1/6)
33% Level 5 (2/6)